commercialisation

News

Roche’s Genentech strikes $2.3bn deal for Hanmi obesity drug...

Roche’s Genentech has agreed a deal worth up to $2.3 billion to develop and sell Hanmi Pharmaceutical’s experimental obesity drug HM17321.

Market Access

The new commercialisation playbook: What BIO 2026 taught eme...

BIO International focused on how emerging biotech companies should approach their first product launch outside the United States, typically in Europe.

Sales & Marketing

Why Medical Affairs must be integrated into field strategy

Many organisations still operationalise Medical Affairs as a downstream contributor, rather than an integrated strategic partner.

Market Access

Company Profile: Acumetis

Acumetis is a global expert commercialisation partner purposefully built to help life sciences companies win in the age of connectivity.

Sales & Marketing

lady looking at device, with a colourful background

Solution Spotlight: InConcert for pre-launch

Inizio InConcert brings together engagement data, field insight, and clinical indicators to help teams see how readiness is taking shape.

R&D

12 Questions with Matthew Goodman

LUCENT Biopharma's Medical Director Matthew Goodman, a doctor by training, specialises in late-phase Clinical Development and Medical Affairs.